MeiraGTx Holdings plc
NASDAQ:MGTXBiotechnology
+$0.53 today
- Market cap
- $826.80M
- Beta
- 1.26
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.48
Volume 0.83M
Average 0.84M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MeiraGTx Holdings plc
NASDAQ:MGTX
Intrinsic Alpha fair value
Locked
Current Price
$8.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +72.3% | +48.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +72.3% over three years. Forward estimates point to Revenue at +48.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Krystal Biotech, Inc. NASDAQ:KRYS | $9.05B | $305.23 | Undervalued | 44.5 | +45.82% |
uniQure N.V. NASDAQ:QURE | $1.67B | $23.81 | Not rated | -14.1 | -30.06% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +15.47% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Sana Biotechnology, Inc. NASDAQ:SANA | $605.26M | $2.02 | Not rated | -3.5 | -46.74% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | $7.64 | Not rated | -1.5 | -35.64% |
Ocugen, Inc. NASDAQ:OCGN | $280.88M | $0.83 | Not rated | -5.6 | -34.20% |
Lineage Cell Therapeutics, Inc. AMEX:LCTX | $231.31M | $0.91 | Not rated | -4.6 | -53.91% |
Continue the stock analysis
Jump to another research area for this company.